Yesterday, the Home Secretary confirmed the Government will make cannabis-derived medicinal products available in the UK.
The news comes following the Advisory Council on the Misuse of Drugs (ACMD) recommendation that cannabis-derived medicinal products should be able to be prescribed by clinicians. The ACMD advises the government on the control of drugs across the UK.
What happens next?
The Government plans to reschedule cannabis-derived medicinal products by this autumn. In theory this means cannabis would be available on prescription. However, it's still unclear what the system will look like and when cannabis will be actually available for those who could benefit.
Evidence clearly shows that cannabis for medicinal use can help people with MS to manage pain and spasms. It is crucial that people with MS, who could benefit, are able to access cannabis-based medicinal products when they are available.
The Government must now begin working to develop a framework and clinical guidance that allows the safe prescribing of cannabis-derived medicinal products.
We’ll continue working to ensure people with MS who could benefit will be able to access this vital treatment.
Genevieve Edwards, our Director of External Affairs, said:
“This is exceptional news and we want to thank the Home Secretary for the speed at which this decision has been made. We started campaigning for cannabis for MS exactly a year ago and it’s incredible to see how far we’ve come since then. The priority now has to be making sure everyone who could benefit can access cannabis in a safe and responsible way.
“We plan to work closely with the Government to determine what exactly this will mean for people with MS. This life-changing decision could help thousands with the condition who haven’t been able to find relief for their pain and muscle spasms.”